LOGO
LOGO

Clinical Trial Calendar

Results Date
Company Name
Ticker
Event
Indication
Outcome
Early 2026
Immatics N.V
IMTX
Pre-specified interim analysis data from Phase 3 trial of ACTengine IMA203
Second-line or later (2L+) unresectable or metastatic melanoma
Early 2026
Contineum Therapeutics Inc.,
CTNM
Topline data readout from Phase 1b trial of PIPE-791
Chronic pain associated with two separate indications, osteoarthritis (OA) and low back pain (LBP)
Early 2026
MoonLake Immunotherapeutics
MLTX
Topline data from Phase 2 trial of sonelokimab (S-OLARIS)
Axial spondyloarthritis (axSpA)
Positive results reported on Feb 22, 2026
Early 2026
Beam Therapeutics Inc.
BEAM
Further data from dose-escalation portion of Part A of Phase 1/2 trial of BEAM-302
Alpha-1 antitrypsin deficiency (AATD)
Updated clinical data reported from the Phase 1/2 trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on 25th March 2026.
Early 2026
Iovance Biotherapeutics, Inc.
IOVA
Initial results from Phase 2 trial of Lifileucel (IOV-END-201)
Advanced endometrial cancer
Early 2026
AC Immune SA
ACIU
Interim results from Phase 2 trial of ACI-24.060 (ABATE)
Alzheimer's disease
Early 2026
BridgeBio Pharma, Inc.
BBIO
Topline results from Phase 3 trial of infigratinib (PROPEL 3)
Achondroplasia
Positive topline results reported on Feb 12, 2026
Early 2026
Aclaris Therapeutics
ACRS
Top line results from Phase 1a single ascending dose and multiple ascending dose portion of Phase 1a/1b trial of ATI-052
Immune-inflammatory diseases
Q2 2026
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI, RICFY
Top-line results from Phase 2 trial of pasireotide
Post-bariatric hypoglycemia
Q2 2026
AN2 Therapeutics, Inc.
ANTX
Data from Phase 1 first-in-human clinical trial and a non-human primate efficacy study of oral AN2-502998
Chronic Chagas disease
Q2 2026
Avadel Pharmaceuticals plc
AVDL
Data from Phase 3 trial of LUMRYZ (REVITALYZ)
Idiopathic hypersomnia (IH)
Q2 2026
Wave Life Sciences Ltd.
WVE
Six-month follow-up data from 400 mg Cohort 3 of Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Wave Life Sciences Ltd.
WVE
Three-month follow-up data from 600 mg Cohort 4 Phase 1 trial of WVE-007 (INLIGHT)
Obesity
Q2 2026
Cullinan Therapeutics, Inc.
CGEM
Initial data from Phase 1 study of CLN-978 (OUTRACE)
Rheumatoid arthritis (RA)
Q2 2026
Mirum Pharmaceuticals Inc.
MIRM
Topline data from Phase 2b study of Volixibat (VISTAS)
Cholestatic pruritus in patients with primary sclerosing cholangitis
Q2 2026
Kodiak Sciences Inc.
KOD
Topline data from Phase 3 trial of Tarcocimab (DAYBREAK)
Wet Age-Related Macular Degeneration
Q2 2026
Kodiak Sciences Inc.
KOD
Topline data from Phase 3 trial of KSI-501(DAYBREAK)
Wet Age-Related Macular Degeneration
Early Q2 2026
Lipocine Inc
LPCN
Topline safety and efficacy results from Phase 3 trial of LPCN 1154 (oral brexanolone)
Postpartum depression
study fails; reported on Apr 2, 2026
Q2 2026
Atrium Therapeutics, Inc.
RNA
Topline data from Phase 3 trial of delpacibart etedesiran (HARBOR)
Myotonic dystrophy type 1 (DM1)
Q2 2026
Curasight A/S
CUS.F
Topline data from Phase 1 trial of uTREAT
High-grade gliomas
Q2 2026
Ascendis Pharma A/S
ASND
78-week data from Phase II Trial of TransCon CNP in combination with TransCon hGH (COACH)
Achondroplasia in children
Q2 2026
NextCure Inc
NXTC
Data from Phase 1 open-label dose escalation study of SIM0505 (CDH6 ADC)
Advanced solid tumors including gynecological cancers and platinum resistant ovarian cancer
Q2 2026
Aquestive Therapeutics Inc.
AQST
Data readout from second Phase 1 trial of AQST-108
Alopecia areata (AA)
Q2 2026
Candel Therapeutics, Inc.
CADL
Follow-up clinical data from phase 3 trial of Aglatimagene besadenovec (CAN-2409)
Prostate cancer
Q2 2026
Coherus Oncology, Inc.
CHRS
Initial data from Phase 1b dose optimization study of CHS-114 in combination with toripalimab
Second-line head and neck squamous cell carcinoma (HNSCC)
Buy this Content
Editors Pick
gsk 09062026 lt

Nuvalent Stock Climbs 39% On $10.6 Bln Takeover Deal With GSK

June 09, 2026 08:05 ET
chatgpt 09062026 lt

OpenAI Joins IPO Race With Confidential S-1 Filing

June 09, 2026 05:10 ET
tateandlylev2 08062026 lt

Tate & Lyle Stock Up On $3.6 Bln Cash Deal To Be Bought By Ingredion

June 08, 2026 07:11 ET
spacexx 26032026 lt

SpaceX Aims To Raise Around $75 Bln In IPO, Musk May Become World's First Trillionaire

June 04, 2026 07:12 ET
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap